Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. No gender limit, patients aged between 18 and 80 years (inclusive); 2. Diagnosed as general type of COVID-19 according to the criteria of Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (Trial Version 9); 3. Patients who are willing to participate and provided written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Subjects in the treatment or active stage of malignant tumor; 2. Subjects with known intolerance to inhalation therapy; 3. Subjects with known mental abnormality or cognitive impairment that prevents informed consent; 4. Subjects with immune dysfunction, long-term use of corticosteroids or other immunosuppressants; 5. Subjects with severe heart, liver and kidney dysfunction or serious primary diseases of the system; Acute exacerbation of chronic obstructive pulmonary disease; Acute attack of bronchial asthma; 6. Non-expectorant antioxidant drugs, including large doses of vitamin C and vitamin E; 7. Subjects participating in clinical trials of other drugs or devices; 8. Pregnant or lactating subjects; 9. Other conditions assessed by the investigator as unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to negative viral nucleic acid detection from the start of the study treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Negative rate based on viral nucleic acid detection;Imaging evalution indicators;Clinical effectiveness within 7 days;Recovery rate and time to recovery of main symptoms;Oxygen saturation; | — |
Countries
China
Contacts
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine